Title : Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Pub. Date : 2016 Nov

PMID : 27617661






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo. Platinum collagen type XI alpha 2 chain Homo sapiens